Cyclophosphamide
- Generic Name
- Cyclophosphamide
- Brand Names
- Procytox
- Drug Type
- Small Molecule
- Chemical Formula
- C7H15Cl2N2O2P
- CAS Number
- 50-18-0
- Unique Ingredient Identifier
- 6UXW23996M
- Background
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
- Indication
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
- Associated Therapies
- -
Biomarker Guided Treatment in DLBCL
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2019-07-19
- Last Posted Date
- 2020-11-19
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 128
- Registration Number
- NCT04025593
- Locations
- 🇨🇳
Ruijin hospital, Shanghai, Shanghai, China
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
- Conditions
- Triple Negative Breast CancerMultiple MyelomaOvarian CancerPancreatic Ductal AdenocarcinomaNon-Small Cell Lung CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 16
- Registration Number
- NCT04025216
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Conditions
- Juvenile Myelomonocytic LeukemiaMyelodysplastic SyndromesAcute Myeloid LeukemiaMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT04024761
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer
- Conditions
- HER2-positive Early Breast Cancer
- Interventions
- Drug: Pertuzumab IVDrug: Pertuzumab and Trastuzumab FDC SCDrug: Trastuzumab IVDrug: DoxorubicinDrug: CyclophosphamideDrug: DocetaxelProcedure: SurgeryRadiation: Post-Operative RadiotherapyDrug: Hormone Therapy
- First Posted Date
- 2019-07-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT04024462
- Locations
- 🇨🇳
Shandong Cancer Hospital, Jinan, China
🇨🇳The 900th Hospital of PLA joint service support force, Fuzhou, China
🇨🇳Sun Yet-sen University Cancer Center, Guangzhou City, China
FT516 in Subjects With Advanced Hematologic Malignancies
- Conditions
- Acute Myelogenous LeukemiaB-cell Lymphoma
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 72
- Registration Number
- NCT04023071
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸Mayo Clinic, Phoenix, Arizona, United States
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
- Conditions
- Brain Tumor, RefractoryBrain CancerCNS CancerBrain TumorCNS TumorMedulloblastoma, Non-WNT/Non-SHHCNS NeoplasmBrain Tumor, RecurrentMedulloblastomaMedulloblastoma Recurrent
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04023669
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
- Conditions
- Hematopoietic and Lymphoid System Neoplasm
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: BendamustineDrug: CyclophosphamideBiological: Filgrastim-sndzDrug: FludarabineDrug: MelphalanDrug: Mycophenolate MofetilBiological: RituximabDrug: TacrolimusRadiation: Total-Body Irradiation
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04022239
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study
- Conditions
- Thalassemia Major
- Interventions
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- First Affiliated Hospital of Guangxi Medical University
- Target Recruit Count
- 823
- Registration Number
- NCT04009525
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Recurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaCD19 PositiveRefractory Chronic Lymphocytic LeukemiaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular Lymphoma
- Interventions
- Biological: Chimeric Antigen Receptor T-Cell TherapyDrug: CyclophosphamideDrug: Fludarabine PhosphateBiological: Tocilizumab
- First Posted Date
- 2019-07-05
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04007029
- Locations
- 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: ClofarabineDrug: FludarabineDrug: BusulfanProcedure: Total Body Irradiation (TBI)Drug: CyclophosphamideDrug: Granulocyte Colony-Stimulating FactorDrug: TacrolimusDrug: Cellcept
- First Posted Date
- 2019-06-28
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT04002115
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.